Following the successful late-stage study in wet age-related macular degeneration, Ocular plans to meet with the FDA to ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

Feb 17 (Reuters) - Ocular Therapeutix said on Tuesday its experimental eye disease drug was more effective in helping patients maintain their vision compared to Regeneron's approved treatment Eylea in ...

Investors were looking for a greater difference between Ocular’s experimental medicine and a low-dose version of Eylea, ...

Ocular now plans to apply for FDA approval, but whether doctors and insurers will favor its new drug is an open question.

By Kamal Choudhury Feb 17 (Reuters) - Ocular Therapeutix's experimental eye drug showed superiority to Regeneron's Eylea in a key late-stage trial, but its modest advantage and higher rates of certain ...

Eylea HD injected every 12 or 16 weeks controls neovascular age-related macular degeneration to a similar extent as Eylea ...

Few drugs become multi-billion blockbusters, but those that do usually have similar characteristics. They treat big, and growing patient populations; they don't compete with too many other drugs (and ...

TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual ...

Here's why Regeneron (REGN) and Bayer's (BAYRY) fast growing Eylea for AMD is on target to eclipse $2 billion in global sales this year. Few drugs become multi-billion blockbusters, but those that do ...